Melanoma

FDA grants GSK ‘priority review’ on melanoma treatment

FDA grants GSK ‘priority review’ on melanoma treatment

By Michelle Yeomans

The Food and Drug Administration has given GSK a ‘priority review’ on the work it’s been doing on a melanoma treatment, which if approved, will see for the first time, the dual use of ‘Tafinlar’ in the treatment of skin cancer.